Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of Safety, Tolerability and Efficacy of Crofelemer Following Multiple Ascending Doses of Crofelemer Powder for Oral Solution in Pediatric Participants With Microvillus Inclusion Disease (MVID)

NCT06721871 is registered in ClinicalTrials.gov with Napo Pharmaceuticals, Inc. as lead sponsor.

NCT NCT06721871
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06721871 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of Safety, Tolerability and Efficacy of Crofelemer Following Multiple Ascending Doses of Crofelemer Powder for Oral Solution in Pediatric Participants With Microvillus Inclusion Disease (MVID)
Lead sponsor
Napo Pharmaceuticals, Inc.
Phase
Phase 2/3
Overall status
Active, not recruiting
Start date
May 1, 2025
Completion date
December 31, 2026
Enrollment
6 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

congenital disorders, microvillus inclusion disease, rare diseases